HONG KONG – South Korea's Samsung Bioepis Co. Ltd. will get $100 million in up-front payments in a commercialization deal for two of its biosimilar candidates with U.S. company Biogen Inc. Under the deal, Samsung Bioepis will also be eligible for up to $270 million in milestone and option payments, as well as a share of sales revenue.